Voie d'administration: Administration pulmonaire par inhalation de poudre sèche en plusieurs respirations
Type de dispositif: Plateforme DPI rechargeable délivrant 100 à 400 mg par traitement à partir d'un contenant scellé
Compatibilité posologique: Compatible avec les poudres cohésives, les produits biologiques et le repositionnement de médicaments pour la mucoviscidose, la tuberculose, l'HTAP, la FPI et le cancer du poumon
Réutilisabilité: Conception rechargeable, un seul contenant par traitement

Autres informations

Description supplémentaire:

Orbital™ DPI is Aptar Pharma's next-generation dry powder inhaler platform built for high-dose pulmonary drug delivery. Designed around patient needs, it enables progressive dispensing from a sealed puck, so multiple gentle inhalations deliver a large powder payload without reloading, minimizing cough reflex and improving comfort, which suits severe respiratory conditions and niche therapies. The device accommodates cohesive powders, biologics and drug-repurposing needs, offering flexibility for small molecules and complex formulations, and integrates digital health connectivity for real-time adherence monitoring and data-driven insights that strengthen trials and patient outcomes. Its propellant-free design supports sustainability goals, while ergonomic features keep it easy to use, with global applicability spanning cystic fibrosis, pulmonary infections, PAH, IPF and oncology.